[go: up one dir, main page]
Cetuximab

"Cetuximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
Definition   |   Details   |   More General Concepts   |   Related Concepts   |   More Specific Concepts
A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.


expand / collapse Publications
This graph shows the total number of publications written about "Cetuximab" by people in this website by year, and whether "Cetuximab" was a major or minor topic of these publications.
Below are the most recent publications written about "Cetuximab" by people in Profiles.
  1. Modeling critical dosing strategies for stromal-induced resistance to cancer therapy. NPJ Syst Biol Appl. 2025 Feb 06; 11(1):16.
    View in: PubMed
  2. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncol. 2024 Dec; 25(12):1576-1588.
    View in: PubMed
  3. Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors. Br J Cancer. 2024 Nov; 131(8):1328-1339.
    View in: PubMed
  4. Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). J Natl Cancer Inst. 2024 Sep 01; 116(9):1487-1494.
    View in: PubMed
  5. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. J Clin Oncol. 2024 Jun 01; 42(16):1890-1902.
    View in: PubMed
  6. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. Eur J Cancer. 2024 Apr; 201:113914.
    View in: PubMed
  7. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):271-278.
    View in: PubMed
  8. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. J Clin Oncol. 2024 Feb 01; 42(4):399-409.
    View in: PubMed
  9. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Target Oncol. 2023 Nov; 18(6):853-868.
    View in: PubMed
  10. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Res Commun. 2023 10 11; 3(10):2074-2081.
    View in: PubMed
People
People who have written about this concept.
Explore @UCSF
_
Similar Concepts expand description
Similar concepts derived from published works.
_
Top Journals
Top journals in which articles about this concept have been published.

UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB04.

Copyright © The Regents of the University of California.